MiniMed Group, Inc. MMED
- Market cap
- $5.8B
- P/E
- 0.0×
Follow MMED
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 10.65 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 24.43 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 3,000 | 2,800 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 1 | 1 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 2,469 | 2,715 | 3,102 |
Revenue
|
|||
| — | — | — | — | — | — | — | 58.20% | 56.28% | 54.16% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | (70) | (147) | (189) |
EBT
|
|||
| — | — | — | — | — | — | — | (2.84%) | (5.41%) | (6.09%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (107) | (198) | (317) |
Net Income
|
|||
| — | — | — | — | — | — | — | 129 | 143 | 156 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 9.77 | 10.74 | 12.09 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (0.42) | (0.78) | (1.29) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | 0.16 | 0.55 | (0.77) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (0.59) | (0.76) | (0.87) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (0.42) | (0.21) | (1.64) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 13.17 | 14.07 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 253 | 253 | 257 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 1.35 | 1.35 | 0.86 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (10.58) | (10.58) | (6.40) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | 41 | 140 | (197) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (148) | (193) | (223) |
Capex
|
|||
| — | — | — | — | — | — | — | (107) | (53) | (420) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 229 | 646 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (11) | (298) |
Net Debt
|
|||
| — | — | — | — | — | — | — | 0 | 3,330 | 3,611 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (10.14%) | (7.54%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | (2.73%) | (3.58%) |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | (9.59%) |
ROE
|
|||
MiniMed Group, Inc. (MMED) key facts
- MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
- MiniMed Group, Inc. reported a net loss of $317.0 million, or a loss of $1.29 per share, for fiscal 2026.
- As of September 25, 2026, MMED traded at $19.98, a market capitalization of $5.8 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.8× sales.
- Return on equity was −9.59% and debt-to-equity 0.00.
MiniMed Group, Inc. (MMED) Latest News
22 Sep
MiniMed Group, Inc. posted Q1 FY2027 results for the quarter ended July 31, 2026: worldwide net sales rose 16.6% (15.8% organic) to $843 million, with U.S. sales up 13.1%. Management raised full-year organic revenue growth guidance to about 10.5%. Nine analysts increased targets to the high-20s on pipeline momentum: MiniMed Fit submitted to the FDA with a summer 2027 U.S. launch; Flex CE Mark; Vivera trial enrollment; and IDE for a next-gen extended-wear sensor. New pumps grew >20% YoY; CGM attachment reached 69%. But free cash flow was negative $90 million, driven by $111 million of separation costs for MMED and other one-time items; EBITDA margin fell to 9.9% after $8 million of pull-forward spending and a $12 million currency remeasurement charge. An extra week in the quarter boosted reported growth by 4-6 points and is expected to normalize. Hedge funds increased ownership; the key question is whether Fit/Vivera timing justifies the near-term cash burn. Pipeline milestones and higher guidance signal meaningful upside, but near-term profitability is constrained by separation costs.
14 Sep
MiniMed Group, Inc. filed Form S-4 registration statement tied to Medtronic exchange offer. Form S-4 filing for Medtronic exchange offer marks major strategic transaction likely to alter ownership, operations and investor outlook.
Medtronic launches an exchange offer to complete the separation of MiniMed Group, Inc. Separation from Medtronic positions MiniMed as an independent entity with altered strategic and market dynamics.
10 Sep
MiniMed Group’s new pump lineup gains traction with patients, driving increased adoption. New pump lineup adoption strengthens MMED market position and sales outlook.
8 Sep
MiniMed (MMED) conducted its Q1 2027 earnings call. Q1 2027 earnings call provides financial results and guidance that can shift investor sentiment and company trajectory.
4 Sep
MiniMed Group, Inc. (MMED) stock soared this week. Stock price surge signals moderate market reaction likely tied to company-specific developments.
3 Sep
MiniMed Group (MMED) starts fiscal 2027 with strong performance driven by product advancements and regulatory progress. Product and regulatory progress builds MMED's trajectory through major strategic and competitive gains.
1 Sep
MiniMed Group Inc (MMED) reported strong Q1 2027 revenue growth and raised its financial outlook. Strong revenue growth and raised outlook signal major positive shifts in financial trajectory and market sentiment.
Medtronic nears a potential breakout while its spinoff MiniMed Group hits a record high. MiniMed record high drives strong investor sentiment and lifts near-term stock performance.
MiniMed Group Q1 earnings call highlighted revenue figures, operational updates, and forward guidance for product development and market expansion. Q1 earnings call details directly shape financial outlook and investor positioning for MMED.
Medtronic spun off diabetes operations into MiniMed Group, whose shares surged post-announcement. Earnings will reveal revenue trends, profitability, product pipeline progress, and guidance that shape standalone trajectory. Diabetes spinoff and share surge mark major strategic separation that can significantly alter MiniMed's performance path and sentiment ahead of earnings.
MiniMed Group, Inc. (MMED) reports accelerated U.S. growth marking a strong start to fiscal year 2027. Accelerated U.S. growth points to major positive momentum likely to boost financial results and investor outlook.
MiniMed (MMED) shares surge on revenue growth and raised price targets while hedge fund conviction weakens. Revenue growth and price target increases point to moderate effects on near-term performance without evidence of major strategic shifts.
20 Aug
MiniMed Group ships MiniMed Flex device integrated with Abbott's smallest Instinct sensor. Commercial shipment of new integrated product strengthens market position and revenue potential.
Abbott Laboratories' Instinct Sensor could provide MiniMed Group a competitive edge. Potential use of Abbott sensor technology may improve MiniMed product positioning.
17 Aug
MiniMed Group, Inc. begins shipping its smallest app-controlled insulin pump paired with the world's smallest sensor. MiniMed launches shipping of smallest app-controlled insulin pump with world's smallest sensor, strengthening product edge in diabetes care market.
29 Jul
MiniMed Group, Inc. (MMED) stock nears Dividend King status while Wall Street projects further upside potential. Dividend milestone proximity and positive analyst outlook may lift investor sentiment and share performance.
27 Jul
MMED obtains Medicare coverage for Flex, broadening diabetes care access. Medicare coverage approval expands market access and revenue potential for MMED diabetes products.
22 Jul
MiniMed Flex™ is now available to Medicare and Medicare Advantage beneficiaries. Medicare availability expands MiniMed Flex access to millions of potential users and drives substantial revenue growth.
17 Jun
MiniMed Group, Inc. launches its smallest app-controlled insulin pump for availability across the U.S. market. U.S. launch of smallest app-controlled insulin pump represents major product introduction with direct revenue and competitive effects.
4 Jun
Medtronic stock has bottomed, positioning the company for a healthy rebound ahead with positive implications for future performance. Rebound outlook points to moderately noticeable effects on MMED market trajectory.
Abbott launches tech innovation addressing a major gap in diabetes care. Abbott diabetes tech directly competes with MiniMed core offerings and may pressure market share.
3 Jun
MiniMed Group Inc (MMED) posted record Q4 2025 revenue in its earnings call alongside strategic product updates aimed at future growth. Record revenue and new product strategy signal major trajectory shift for MMED.
MiniMed Group, Inc. will expand its sensor portfolio with integrated dual glucose-ketone sensors produced by Abbott. Dual glucose-ketone sensor integration marks a major product expansion that can shift competitive positioning and trajectory.
MiniMed Group, Inc. (MMED) will expand its sensor portfolio with integrated dual glucose-ketone sensors manufactured by Abbott. Abbott collaboration for dual sensors enables major product expansion that can significantly boost MMED market position in diabetes monitoring.
MiniMed Group, Inc. (MMED) delivered strong fourth quarter and full fiscal year 2026 financial results while providing an outlook for fiscal year 2027. Strong earnings results and 2027 guidance can significantly boost market valuation and investor sentiment.
Medtronic stock rises against market selloff following earnings release. Medtronic earnings affect sentiment and performance for its MiniMed diabetes unit.
MiniMed Group reported Q4 results during its earnings call, covering revenue, profitability metrics, operational updates, and forward guidance for the company. Q4 earnings figures and guidance directly shape near-term valuation and trading activity for MiniMed Group.
22 May
MiniMed Group Inc (MMED) released a study confirming the effectiveness of its 780G SmartGuard Algorithm. Confirmation of core algorithm performance may modestly improve product credibility and market perception.
21 May
New study confirmed consistent glycemic outcomes across sensors integrated with MiniMed 780G System. Positive validation of MiniMed 780G sensor performance supports product reliability and may improve market sentiment.